BioSpace News Archive

Hansa Biopharma has been invited to participate in two global biotech and healthcare conferences during March including Cowen Annual Health Care Conference in Boston and Carnegie Nordic Healthcare Seminar in Stockholm

HELSINKI , Feb. 25, 2020 /PRNewswire/ -- Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson’s disease patients, with encouraging biological responses as measured by PET imaging in some patients. Results from the second part of trial, in which all patients will receive CDNF for an additional six months, are expected in Q3 2020. H

Feb. 25, 2020 08:05 UTC First in-vivo T cell therapy to demonstrate clinical activity in hard-to-treat solid tumor 79% of evaluable patients achieved disease control on target lesions; 53% experienced tumor regressions 37% achieved durable clinical benefit lasting ≥ 6 months; including four partial regressions so far, overall response rate not yet reached as six patients remain on treatment Treatment well-tolerated with limited side effects observed IMV t

Funds will be used for advancing the Company’s next generation immuno-oncology drug candidates, including lead anti-CD47 product for the treatment of solid tumors through Phase I/II study in addition to advancing preclinical pipeline

Agreement in Principle with Court-Appointed Plaintiffs’ Executive Committee Representing the Interests of Thousands of Plaintiffs in the Opioid Multidistrict Litigation; Supported by a Broad-Based Group of 47 State and U.S. Territory Attorneys General

United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will participate in a fireside chat covering the company’s business at the 40th Annual Cowen & Company Healthcare Conference in Boston, Massachusetts.

Pinpoint Science Inc. today announced a strategic collaboration with Analog Devices, Inc. to advance the development and manufacture of novel nanosensor diagnostics that aim to deliver highly accurate results in under a minute.

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Chief Executive Officer Raymond W. Cohen is scheduled for a fireside chat at the Barclays Global Healthcare Conference,

Viseon, Inc. today announced the closing of their $18.0 million Series-B financing. The financing was co-led by Invus Opportunities (New York, NY), affiliates of Wexford Capital LP (Greenwich, CT and West Palm Beach, FL) and HBM-MedFocus (Irvine, CA).

Peptilogics, a clinical-stage biotechnology company developing a computational peptide therapeutics discovery platform and novel best-in-class anti-infective compounds, announced today that it has entered into an agreement with CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating antibacterial research and development.